Prognostic Impact of CHOI Response Criteria Compared to RECIST in Grade 1-2 Advanced Pancreatic Neuroendocrine Tumors (CRIPNET-GETNE Study-NCT02841865)

#2217

Introduction: Response Evaluation Criteria In Solid Tumors (RECIST) are not presumably the most optimal option for predicting the benefit of antiangiogenic drugs in neuroendocrine tumors (NETs), given that tumor shrinkage is not frequent, and qualitative changes in tumor tissues are to be expected.

Aim(s): The aim is to assess the performance of CHOI response criteria vs RECIST v1.1 in patients with advanced grade 1-2 pancreatic NETs treated with sunitinib.

Materials and methods: Concordance between both methods, CHOI criteria and RECIST, was evaluated with the Cohen's kappa statistic. The landmark method was used to take into account the time-dependent nature of the treatment response variable, and the Mantel Byar test was applied to compare survival curves.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Carmona-Bayonas A, Fernandez del Valle A, Solis M, Matos I, Garcia-Carbonero R,

Keywords: CHOI criteria, pancreatic neuroendocrine tumor, RECIST, response, survival,